Tavapadon (Juvmo) is a new once-daily pill for Parkinson’s motor symptoms. Here’s how it works, who it may help and what to ...
Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...
The Brighterside of News on MSN
Long-term air pollution exposure linked to Parkinson’s disease risk
A Cambridge review links long-term particle pollution with increased Parkinson’s risk while highlighting major research gaps.
Although a clinical setback last year continues to loom in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics ...
AbbVie stock (ABBV) slipped slightly on Monday, down 0.29%, after the company announced a major regulatory win. The FDA ...
The FDA has approved Juvmo, the first and only dopamine agonist for adults with Parkinson’s disease designed to selectively ...
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...
Health and Me on MSN
CSIR-CCMB scientists find flu & COVID viruses may affect a protein linked to Parkinson’s disease
Researchers at CSIR-Centre for Cellular and Molecular Biology (CCMB) have found possible links between RNA viruses like ...
2d
AskBio’s bold ambition to help people with Parkinson’s disease look forward — and maybe even tango
"Among the aims of the research team is to better understand whether gene therapy may one day provide a different approach to ...
The FDA approved AbbVie’s once-daily oral drug Juvmo (tavapadon) for adults with Parkinson’s disease. Phase 3 trials found ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results